Is 2493.HK overvalued or undervalued?

2493.HK currently has a P/E ratio of -7.37. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Mabwell-b stock?

Mabwell-b trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2493.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2493.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2493.HK to protect their purchasing power. Because 2493.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2493.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2493.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2493.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2493.HK

Mabwell-b

HK$20.38+HK$0.02+0.10%

HKSE / HKD

Market cap

HK$11.3B

P/E

-7.4

EPS (TTM)

HK$-0.34

Dividend yield

—

Beta

0.53

3M return

-13.28%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$3M2021

$4M2022

$18M2023

$27M2024

$95M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity3.84High
Current ratio1.25
Cash ratio0.97
Net margin-107.5%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2493.HK-7.4
Healthcare sector median26.8
S&P 50022.0

Trades about 128% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.43
Price to book7.90
EPS (TTM)HK$-0.34
Payout ratio-473%
FCF yield-4.70%

Range & risk

HK$19.80HK$29.18

Trading in the lower third of its 52-week band

Beta0.53

Profile

What Mabwell-b actually does

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.

CEO

Datao Liu

Employees

1,325

Headquarters

Shanghai, SH

Founded

2026-05-12

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2493.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2493.HK has a beta of 0.53, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Mabwell-b